Impact of positive CD4 cells on event‐free survival in follicular lymphoma patients
Open Access
- 9 September 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (17) , e70117
Abstract
Objective: Previous results about prognostic value of CD4+ T cells in follicular lymphoma (FL) remain controversial.Methods: Immunohistochemistry was used to examine expression of positive CD4 cells in 103 patients with FL 1‐3A. Early failure was described as failing to achieve event‐free survival (EFS) at 12 or 24 months.Results: There were 49 (47.6%) male and 54 (52.4%) females, with a median age of 54 years. Compared to patients with p = 0.047). When patients were stratified based on positive CD4 cell combined with FLIPI, the median EFS (p = 0.002) and median OS (p = 0.007) were significantly different.Conclusions: This study demonstrated that higher expression of positive CD4 cells predicts lower risk of early failure in follicular lymphoma, and combination analysis of CD4 and FLIPI could better predict disease relapse and survival outcome.Keywords
This publication has 37 references indexed in Scilit:
- Cytotoxic CD4+ T cells eliminate senescent cells by targeting cytomegalovirus antigenCell, 2023
- Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphomaBlood Cancer Journal, 2021
- Vulnerabilities in the tumor and microenvironment in follicular lymphomaHematological Oncology, 2021
- Immune infiltrate diversity confers a good prognosis in follicular lymphomaCancer Immunology, Immunotherapy, 2021
- Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysisInternational Immunopharmacology, 2020
- A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohortsThe Lancet Oncology, 2018
- Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patientsHuman Pathology, 2017
- Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryThe Lancet Oncology, 2015
- Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trialThe Lancet Oncology, 2014
- Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cellsLeukemia, 2011